A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

John Thomas Barrett, Bruno Orofiamma, Janardan D. Khandekar, Paul P. Carbone, Robert L. Comis, Thomas E. Davis

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

Original languageEnglish (US)
Pages (from-to)2445-2447
Number of pages3
JournalCancer
Volume64
Issue number12
DOIs
StatePublished - Dec 15 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract'. Together they form a unique fingerprint.

  • Cite this